Renovaro Secures U.S. Patent To Boost Its AI Drug Discovery And Diagnostics Platform

Renovaro Inc., a clinical-stage precision medicine company, has announced that its subsidiary, BioSymetrics, has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions” (Application No. 18/058,752). The patent is an important addition to Renovaro’s growing intellectual property portfolio focused on artificial intelligence and machine learning technologies. 

It covers innovative methods for integrating and harmonizing various types of biomedical data including genomics, electronic health records, imaging, and clinical trial data into a unified framework. This framework supports predictive modeling efforts that are crucial for drug discovery and development. This new patent builds on a foundational patent (US 11,379,757), which was granted in July 2022. That earlier patent focused on optimizing machine learning pipelines through advanced techniques such as feature selection and model tuning. 

David Weinstein, CEO of Renovaro, stated, “This patent is a strategic milestone for Renovaro. Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights.”

The newly allowed patent extends this work by addressing the practical challenge of working with fragmented and diverse datasets, which is a significant hurdle in pharmaceutical research and clinical decision-making. The patented methods are designed to function within distributed and parallel computing environments. This enables scalable and real-time predictive analytics, a capability that is becoming increasingly important as the biopharma industry adopts AI-driven approaches to improve research efficiency, lower costs, and speed up the development of new treatments.

The allowance of this patent also supports Renovaro’s broader business strategy. By protecting its unique technology, the company strengthens its position for future commercial partnerships, licensing deals, and the broader deployment of its platforms in life sciences and healthcare. It also enhances Renovaro’s ability to support applications in rare diseases, clinical trials, and personalized medicine. Overall, the new patent marks another step forward in Renovaro’s efforts to deliver cutting-edge solutions that create value for patients, collaborators, and shareholders.